Context: Acquired generalized lipodystrophy (AGL), a rare disorder characterized by loss of subcutaneous adipose tissue, is estimated to occur in association with autoimmune diseases in~25% of the cases. Common variable immunodeficiency (CVI) is a condition known for its strong association with autoimmune diseases often occurring with negative autoantibodies. To the best of our knowledge, we describe the first known case of AGL in a patient with CVI.
A cquired generalized lipodystrophy (AGL) is a rare disorder characterized by the loss of subcutaneous adipose tissue that generally occurs during childhood and adolescence (1) . This condition leads to severe insulin resistance and hyperglycemia and has been estimated to occur in association with autoimmune diseases in 25% of the cases (1) .
To the best of our knowledge, we describe the first known case of AGL in a patient with common variable immunodeficiency (CVI), a condition known for its strong association with autoimmune diseases (2, 3) .
Case Report
A 24-year-old man was referred to our center with a history of decompensated diabetes mellitus [glycosylated Hb (HbA1c), 12.1%] associated with high levels of triglycerides (1600 mg/dL) and hepatomegaly. He required basal and bolus insulin (total dose, 0.8 U/kg).
The diabetes had been diagnosed 2 years previously, when the patient had presented with weight loss, polyphagia, and polyuria. The patient had never achieved good glycemic control with oral diabetic medications or insulin. He showed a clearly identifiable pattern of fat loss on his face, trunks, and limbs, which immediately raised the possibility of acquired lipodystrophy (Fig. 1) . When questioned, the patient reported that he had been slightly fat and strong until 2 years earlier, which was confirmed by a photograph that had been taken 3 years earlier (Fig. 2) . He had a history of a single episode of severe pneumonia during childhood.
On physical examination, the patient had a body mass index of 21.5 kg/m 2 and a clear pattern of generalized fat loss. His liver was palpable 3 cm below the right costal margin. No signs of acanthosis nigricans were present.
Laboratory tests (Table 1) showed the following results: fasting serum glucose, 324 mg/dL [normal range (NR), ,126 mg/dL]; HbA1c, 12.1% (NR ,6.5%); total cholesterol, 376 mg/dL (NR, ,200 mg/dL); high-density lipoprotein cholesterol, 27 mg/dL (NR, .45 mg/dL); lowdensity lipoprotein cholesterol, 27 mg/dL (NR, ,100 mg/dL); triglycerides, 1621 mg/dL (NR, ,150 mg/dL); alanine aminotransferase, 87 U/L (NR, ,41 U/L); aspartate aminotransferase, 82 U/L (NR, ,37 U/L); TSH, 26.9 mIU/mL (NR, 0.8 to 4.0 mIU/mL); free T4, 0.61 ng/ dL (NR, 0.7 to 1.6 ng/dL); and negative antithyroperoxidase and antithyroglobulin antibodies. Type 1 diabetes mellitus (T1DM) was excluded by the patient's clinical presentation, absence of glutamic acid decarboxylase antibody autoantibodies, and C-peptide level of 3.1 ng/dL (NR, 0.4 to 3.6 ng/dL). Measures of insulin resistance, including homeostatic model assessment for insulin resistance, could not be performed because withdrawal of exogenous insulin was prevented by the patient's failure to achieve optimal glycemic control. Leptin and adiponectin were later measured, and both values were less than the lower limit of detection (Table 1) .
A whole-body dual energy x-ray absorptiometry scan showed a total body fat content of 12.3% (the minimal amount of body fat was 9.4%, observed in the right leg, and the maximal amount was 22.6%, observed in the head). Although these values were within the reference range (4.0% to 25.3% for a body mass index level ,25 kg/m 2 ), they were also in agreement with the data reported for patients with AGL (1).
The thyroid ultrasound findings showed a pattern suggestive of autoimmune thyroiditis. The abdominal ultrasound scan showed an enlarged liver with the following dimensions: total craniocaudal length, 27 cm; right lobe, 17.2 cm; and left lobe, 9.8 cm. He subsequently underwent liver biopsy, which confirmed the presence of steatohepatitis (Kleiner score of 3, .66% of macrovesicular steatosis, and grade 2 hepatocellular ballooning).
A clinical diagnosis of AGL was confirmed by the described findings. Because AGL has been associated in many cases with hypergammaglobulinemia (1, 4), protein electrophoresis was performed. However, in contrast to our expectations, the patient presented with hypogammaglobulinemia ( Table 2 ). All immunoglobulin levels were subsequently measured and repeated ( Table 2) . After a complete medical history failed to suggest any secondary cause for the low immunoglobulins levels observed, the diagnosis of CVI was confirmed (2, 5) . As stated, the patient had had an episode of severe pneumonia infection during childhood but reported no other serious bacterial infections. The patient provided written informed consent for the publication of this case report. 
Discussion
The occurrence of AGL (also known as Lawrence syndrome) is rare, with ,100 cases reported in the literature (1, 6) . AGL is characterized by the substantial loss of adipose tissue from the entire body. Also, because of extreme insulin resistance, these patients usually present with diabetes mellitus, hypertriglyceridemia, and hepatomegaly. The fat loss generally occurs during childhood and adolescence and rarely develops after the age of 30 years (1). The disease can be divided into three variants: (1) type 1, which affects 25% of the patients and occurs after an episode of panniculitis; (2) type 2, which affects another 25% of the patients and has a presumed autoimmune origin owing to its association with other autoimmune disorders; and (3) type 3, which is idiopathic and occurs in 50% of the patients (1).
The uniqueness of our case was its association with CVI, of which hypogammaglobulinemia is the main feature. An immune deficiency disorder, CVI has a prevalence of 1/25,000 to 1/50,000 individuals in the general population. CVI is associated with the loss of antibody production and is diagnosed by low levels of serum IgA, IgG, and/or IgM (2, 7). The diagnosis of CVI is generally established in adults aged 20 to 40 years, and the patients can present with recurrent acute and chronic infections and an increased risk of lymphoma and other cancers (2) . A strong association has also been found between CVI and the occurrence of autoimmune diseases, which will be present in 20% to 25% of the patients, often with negative autoantibody results (5). The autoimmune predisposition occurs because of an immune dysregulation, which produces multiple antibodies against self-antigenic targets. The most common associated autoimmune disorders are idiopathic thrombocytopenic purpura and autoimmune hemolytic anemia, although many others have been reported (2, 5) , including autoimmune thyroiditis, T1DM, anti-IgA antibodies, autoimmune neutropenia, pernicious anemia, juvenile rheumatoid arthritis, systemic lupus erythematosus, psoriasis, autoimmune hepatitis, primary biliary cirrhosis, sicca syndrome, and vitiligo. Physicians treating patients with CVI must be aware of all these potentially associated diseases to appropriately screen and diagnose these conditions. To the best of our knowledge, AGL has never been reported in a patient with CVI, and we believe it should be included in the differential diagnosis of T1DM. It has been estimated that~1.5% of the patients with CVI will present with diabetes, and the epidemiology and clinical presentation of T1DM and AGL can be similar (the affected individuals are young and thin, and a clinical presentation of hyperphagia, weight loss, and increased HbA1c level at diagnosis is not uncommon) (8) . We hypothesized that some patients with a diagnosis of CVI and T1DM might, in fact, have AGL. Because autoantibodies are usually negative in those with CVI, their measurement would probably not be helpful in differentiating between T1DM and AGL. In contrast, measurement of C-peptide levels could be an excellent approach to establish a correct diagnosis, although this test is often not requested or cited in most case reports of T1DM and CVI. The importance of a correct diagnosis of AGL or T1DM is highlighted by the very distinct therapeutic approaches for both, including the use of recombinant leptin to treat AGL (9) . The differential diagnosis of autoimmune liver diseases is also relevant because AGL is associated with an enlarged liver and increased levels of hepatic enzymes (1) . A liver biopsy can be considered to exclude other hepatic diseases or to correctly evaluate fatty liver in the search for nonalcoholic steatohepatitis and fibrosis, which could have prognostic value (10) .
Our patient presented with a loss of adipose tissue at the age of 22 years and CVI, in addition to autoimmune thyroiditis with negative antibodies (an expected finding with CVI), which was suspected from the ultrasound findings. We believe our patient had type 2 AGL owing to the presence of autoimmune thyroiditis and CVI, which is highly associated with autoimmune disorders. In patients with type 2 AGL, fat loss occurs later in life (15 years compared with 7 to 8 years with other AGL types), and diabetes and hypertriglyceridemia occur in 89% and 87.5% of the patients, respectively. The body fat percentage in these patients, measured using different methods, has ranged from 0.3% to 14.7% (1) . The diagnosis of autoimmune disorders will precede the diagnosis of CVI by an average of 7.5 years for most patients (3, 5) . Thus, physicians diagnosing and treating AGL should be aware of the possible association between AGL and CVI to establish the correct diagnosis and refer these patients appropriately, because of the potential treatment with immunoglobulins and requirement for adequate screening for other autoimmune diseases and malignancies (2) .
Conclusions
To the best of our knowledge, we have presented the first case of AGL associated with CVI. We propose that AGL should be added to the list of possible diseases associated with CVI.
